Opinion|Videos|March 19, 2024
Frontline Therapy for Patients With Non-Clear Cell RCC
Martin Voss, MD, reviews data updates from ASCO GU 2024 on the KEYNOTE-B61 study of lenvatinib + pembrolizumab in nccRCC in addition to real-world outcomes in patients with chromophobe RCC.
Advertisement
Episodes in this series
Advertisement
Related to this article
Bladder-sparing options for BCG-unresponsive non-muscle invasive bladder cancer have transformed since 2020, according to Saum Ghodoussipour, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
2
SOHO 2026: Key Updates Across the Multiple Myeloma Continuum
3
Secondary T-Cell Malignancies: Identifying and Counseling After CAR T-Cell Therapy
4
PALOMA-2 Shows Improved Survival vs Historical IV Amivantamab Data
5